Daiichi Sankyo To File Japan Application For Prasugrel In First Half Of 2013
This article was originally published in PharmAsia News
Daiichi Sankyo will file an application in Japan for the approval of antiplatelet drug prasugrel for use in percutaneous coronary intervention in the first half of 2013.
You may also be interested in...
A study of drug approvals over more than three decades shows antimicrobials, including antibacterials, had consistently shorter development and review times than other types of products. While antibacterials were less likely to participate in special US FDA programs designed to help along review, experts said reimbursement reform, not new regulatory flexibility, is needed to help address the crisis of drug-resistant infections.
US FDA commissioner Stephen Hahn emphasized the important role that telemedicine, COVID-19 testing, and agency-reviewed face masks and ventilators have played during the pandemic in a 1 June speech.
Zimmer Biomet has agreed to pay $9.6m to Conformis Inc. to resolve a dispute over personalized joint replacement technology.